Jump to content

Multisystem inflammatory syndrome in children

From Wikipedia, the free encyclopedia
(Redirected from MIS-C)

Paediatric multisystem inflammatory syndrome (PMIS/PIMS/PIMS-TS)
Other names
  • Multisystem inflammatory syndrome in children (MIS-C)[1]
  • Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19[2]
  • Paediatric inflammatory multisystem syndrome (PIMS), temporally associated with SARS-CoV-2 infection (PIMS-TS)[3]
  • Kawa-COVID-19[4]
  • Systemic Inflammatory Syndrome in COVID-19 (SISCoV)[5]
TEM image of SARS-CoV-2, the coronavirus responsible for COVID-19:
PMIS / MIS-C is thought to be caused by an unusual biological response to infection in certain children
SpecialtyPaediatrics
SymptomsFever, abdominal pain, diarrhoea/vomiting, low blood pressure, insufficient blood supply (shock), pink eye, "strawberry tongue", rashes, large lymph nodes, swollen hands/feet, neurological disturbances, among others
ComplicationsCardiac dysfunction; coronary artery abnormalities, including aneurysms; acute kidney injury; coagulopathy
Usual onsettypically 2–6 weeks[6] after COVID-19 exposure
CausesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Diagnostic methodClinical evaluation by specialists
Differential diagnosisAlternative infectious/non-infectious causes, Kawasaki disease
TreatmentIntravenous immunoglobulin (IVIG); corticosteroids; oxygen, supportive care
PrognosisResponse to treatment, generally good; long-term prognosis, unclear[7]
FrequencyRare
Deaths<2% of reported cases

Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome (PIMS / PIMS-TS), or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19.[7] Studies suggest that MIS-C occurred in 31.6 out of 100,000 people under 21 who were infected with COVID-19.[8][9] MIS-C has also been monitored as a potential, rare[10] pediatric adverse event following COVID-19 vaccination.[11] Research suggests that COVID-19 vaccination lowers the risk of MIS-C, and in cases where symptoms develop after vaccine, is likely extremely rare or related to factors like recent exposure to COVID-19.[12] It can rapidly lead to medical emergencies such as insufficient blood flow around the body (a condition known as shock).[7] Failure of one or more organs can occur.[13] A warning sign is unexplained persistent fever with severe symptoms following exposure to COVID-19.[14] Prompt referral to paediatric specialists is essential, and families need to seek urgent medical assistance.[7] Most affected children will need intensive care.[7]

All affected children have persistent fever.[7] Other clinical features vary.[14] The first symptoms often include acute abdominal pain with diarrhoea or vomiting.[7] Muscle pain and general tiredness are frequent,[7] and low blood pressure is also common.[15] Symptoms can also include pink eye, rashes, enlarged lymph nodes, swollen hands and feet, and "strawberry tongue".[6] Various mental disturbances are possible.[6] A cytokine storm may take place,[16] in which the child's innate immune system stages an excessive and uncontrolled inflammatory response.[17] Heart failure is common.[15] Clinical complications can include damage to the heart muscle, respiratory distress, acute kidney injury, and increased blood coagulation.[18] Coronary artery abnormalities can develop (ranging from dilatation to aneurysms).[6]

This life-threatening disease has proved fatal in under 2% of reported cases.[7] Early recognition and prompt specialist attention are essential.[19] Anti-inflammatory treatments have been used, with good responses being recorded for intravenous immunoglobulin (IVIG), with or without corticosteroids.[20] Oxygen is often needed.[7] Supportive care is key for treating clinical complications.[18] Most children who receive expert hospital care survive.[7]

Knowledge of this newly described syndrome is evolving rapidly.[21] Its clinical features may appear somewhat similar to Kawasaki disease, a rare disease of unknown origin that typically affects young children, in which blood vessels become inflamed throughout the body.[15] It can also show features of other serious inflammatory conditions of childhood, including toxic shock and macrophage activation syndromes.[15] Nevertheless, it appears to be a separate syndrome.[22] Older children tend to be affected.[23]

This emerging condition has been defined slightly differently (using different names), by the World Health Organization (WHO),[24] the Royal College of Paediatrics and Child Health (RCPCH),[13] and the Centers for Disease Control and Prevention (CDC).[1] Although the condition is thought to follow SARS-CoV-2 viral infection, antigen or antibody tests are not always positive.[3] Exclusion of alternative causes, including bacterial and other infections, is essential for differential diagnosis.[3] Some general clinical guidance has been provided by the RCPCH,[13] the National Institutes of Health,[23] the American College of Rheumatology,[25] and the American Academy of Pediatrics.[26]

Clusters of new cases have been reported two to six weeks after local peaks in viral transmission.[6] The disease is thought to be driven by a delayed biological mechanism in certain predisposed children.[20] The European Centre for Disease Prevention and Control (ECDC) has rated risk to children in Europe as being 'low' overall, based on a 'very low' likelihood of a child developing this 'high impact' disease.[3] Regarding ethnicity, the condition seems to affect more children of African, Afro-Caribbean, and Hispanic descent, whereas Kawasaki disease affects more of East Asian ancestry.[19] Initial reports regarded children in various parts of Europe and the United States, and it was unclear to what extent the condition had gone unrecognized elsewhere.[24] Reports have since emerged of cases in various other countries around the world.[27][28] In adults, a similar condition has occasionally been reported, which has been called multisystem inflammatory syndrome in adults (MIS-A).[29]

Name

[edit]

The disorder has been called by various names, including:

  • Multisystem inflammatory syndrome in children (MIS-C)[1]
  • Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19[2]
  • Paediatric inflammatory multisystem syndrome (PIMS)[13]
  • Paediatric inflammatory multisystem syndrome, temporally associated with SARS-CoV-2 infection (PIMS-TS)[3][7]
  • Paediatric multisystem inflammatory syndrome (PMIS)[15]
  • Kawa-COVID-19[4]
  • Systemic inflammatory syndrome in COVID-19 (SISCoV)[5]

Background

[edit]
X-ray showing aneurysmal enlargement of the coronary arteries, which is a complication in a Kawasaki syndrome

Symptomatic cases of COVID-19 in children have been relatively uncommon,[30] possibly because they generally experience milder disease.[31] Early infection tends to be associated with mild or no symptoms, while the later pulmonary phase, which can be life-threatening in adults, is usually mild or absent.[32][33] While cases of children with severe symptoms are exceptional, they can occasionally require intensive care.[34][35][36] Fatalities have been rare.[33][37]

In April 2020, a small group of children with evidence of SARS-CoV-2 infection or exposure to COVID-19 were found to display clinical features corresponding to the diagnostic criteria of Kawasaki disease, sometimes accompanied by shock.[34][38] Kawasaki disease is a rare syndrome which mainly affects young children (adult onset has occasionally been reported[39]).[3][40][41] It is a form of vasculitis, where blood vessels become inflamed throughout the body, and it results in a persistent fever.[3] Recovery typically occurs spontaneously, though some children later develop mid-sized or giant coronary artery aneurysms in the heart – a potentially fatal complication.[3][42] Symptoms of toxic shock (a syndrome caused by bacterial toxins) occasionally occur – an association sometimes referred to as 'Kawasaki shock syndrome',[43] which is characterized by systolic hypotension or signs of poor perfusion.[3][44] While the exact cause of Kawasaki disease is unknown, one plausible explanation is that it may stem from an infection triggering an autoimmune and/or autoinflammatory response in children who are genetically predisposed.[45][46] No specific diagnostic test exists for Kawasaki disease, and its recognition is based on various combinations of clinical and laboratory findings (including persistent fever, widespread rashes, enlarged lymph nodes, conjunctivitis, changes to the mucous membranes, and swollen hands and feet).[3][40][47]

Characteristics

[edit]

MIS-C / PIMS-TS is a systemic disorder involving persistent fever, extreme[7] inflammation (hyperinflammation), and organ dysfunction, which is temporally associated with exposure to COVID-19.[1][13] Onset may be delayed or contemporary with ongoing SARS-CoV-2 infection,[48] which may pass without symptoms.[7] The time the syndrome takes to appear following the initial viral infection is debated, though it may develop between the first and second week.[49] Epidemiological data suggest that recognition of the disease may typically be delayed by 2–6 weeks,[6] and usually by 3–4 weeks.[50][7] By the time of presentation, children have often developed antibodies to SARS-CoV-2, but test negative for the virus at RT-PCR.[7]

The condition may match some or all of the diagnostic criteria for Kawasaki disease (i.e. the 'complete' or 'incomplete'/'atypical' subtypes[7][47]),[13] or for Kawasaki disease shock syndrome.[43] It tends to affect all paediatric age groups, ranging from infancy to adolescence.[6][20] It can also share clinical features with other paediatric inflammatory conditions, including toxic shock syndrome, and secondary haemophagocytic lymphohistiocytosis or macrophage activation syndrome.[13][32] Coinfections with other pathogens have been recorded.[3]

Affected children always present with persistent fever.[7] Other clinical features at presentation vary.[50][14] In contrast to acute COVID-19, most children have gastrointestinal symptoms, such as diarrhoea, vomiting, and intense abdominal pain (sometimes severe enough to suggest appendicitis).[7] Muscle pain and feelings of tiredness and general physical weakness are also very common.[7][15] Some Kawasaki-like symptoms that may be present (especially in children under the age of 5)[49] include mucosal changes around the mouth ("strawberry tongue", cracked lips, etc.), red eyes (conjunctivitis without pus), widespread rash (consistent with leukocytoclastic vasculitis[51]), red or swollen hands and feet, and enlarged lymph nodes.[6][14][15] Chest or neck pain may also be present.[52] Severe headache and altered mental state have been reported, along with various neurological disturbances.[6][22][53] Features of meningitis have been reported[14][20] as well as septic encephalopathy,[54] stroke,[54] and Guillain-Barre Syndrome.[55] Some patients present with very low blood pressure and shock, and they may require urgent admission to a paediatric intensive care unit.[15]

Cardiovascular involvement is very frequent.[7][22][49] Acute heart failure is common in the form of left ventricular dysfunction,[15][56] and a left ventricular ejection fraction under 60% is frequent.[18] Shock is often of myocardial – mainly left ventricular – origin.[20] Respiratory symptoms are less common,[22] and are not usually a prominent feature.[20][14][56] When present, breathing difficulties are often linked to shock,[3] and are suggestive of heart failure.[14] Some children display features of a cytokine storm,[14] including extremely high serum interleukin-6 (IL-6) levels,[22] and need inotropic support to maintain cardiac output.[16] Coronary artery abnormalities, such as dilatation, are frequent.[15] Some children have developed coronary artery aneurysms.[14] Electrocardiographic (ECG) abnormalities are common.[15] Other cardiological features sometimes include inflammation of the heart valves (valvulitis) and of the fibrous sac surrounding the heart (pericarditis).[6][56] Echocardiographic features of myocarditis (inflammation of the heart muscle) have been recorded.[6][7]

Affected children consistently show laboratory evidence of hyperinflammation.[15] Pronounced biological markers of inflammation generally include strongly raised erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),[57] procalcitonin, ferritin, and IL6.[15] Low platelet counts and impaired blood clotting (coagulopathy) are also common,[20] with increased levels of D-dimer and fibrinogen.[15] Other haematological features include raised numbers of white blood cells (leukocytosis), characterized by high numbers of neutrophils,[57] with many immature forms, and low numbers of lymphocytes (lymphopaenia).[15] Numbers of red blood cells and platelets may be either normal or decreased.[15] Acute kidney injury and low albumin levels in the blood (hypoalbuminaemia) are common.[32] Low blood sodium levels and raised liver enzymes have been reported.[20] Accumulations of fluid in the lungs (pleural effusion), around the heart (pericardial effusion), and in the abdomen (ascites) have also been reported, consistent with generalized inflammation.[32]

Differences with respect to Kawasaki disease include frequent presentation with gastrointestinal symptoms such as vomiting, diarrhoea, and abdominal pain.[6][7] Neurological involvement also appears to be relatively frequent.[14] It often affects older children, whereas Kawasaki disease usually occurs before the age of five.[7][20] Multiorgan disease appears to be more frequent.[22] Myocarditis and cardiogenic shock seem to be relatively common.[22] Myocarditis may be more evident in older children and adolescents.[49] Preschool children tend to display more Kawasaki-like characteristics.[49] Features of macrophage activation syndrome appear to be more frequent than in Kawasaki disease.[23][55] Characteristic laboratory findings that are not usually encountered in Kawasaki disease include very high levels of ventricular natriuretic peptide (a marker of heart failure),[16] as well as somewhat lower platelet counts, lower absolute lymphocyte counts, and higher CRP levels.[19] Very high troponin levels (suggestive of myocardial damage) are also common.[20][32][22]

Clinical course

[edit]

Clinical course tends to be more severe than with Kawasaki disease.[48] A child's condition can deteriorate rapidly, even in the presence of reassuring laboratory findings.[21] Many children develop shock and heart failure.[7] Most require paediatric intensive care.[7] Supplemental oxygen is often needed, and mechanical ventilation is sometimes used.[7] Most children who receive expert multidisciplinary care survive.[7] In addition to respiratory distress, major complications that may need aggressive supportive care can include myocardial damage, acute kidney injury, and coagulopathy (thrombophilia).[18] In some cases, sustained cardiac arrhythmias have led to haemodynamic collapse and need for extracorporeal membrane oxygenation (ECMO).[15] Deaths have been recorded in a small minority (under 2%) of the cases reported.[7][58] Occasionally, fatalities have followed complications of ECMO.[16] Some children exposed to COVID-19 also appear to have a less severe Kawasaki-like disease.[38] Ventricular function often recovers before discharge from hospital (often after 6–10 days).[7] Coronary artery aneurysms can develop even in the absence of Kawasaki-like features.[6] Their frequency and severity is uncertain.[19] So far, they have been recorded in 7% of reported cases.[7] Long-term prognosis is unclear.[15]

Diagnosis

[edit]
Preliminary WHO case definition[24]

Children and adolescents

  • 0–19 years of age with fever >3 days
And
  • Two of the following:
  1. Rash or bilateral non-purulent conjunctivitis
    or muco-cutaneous inflammation signs
    (oral, hands or feet)
  2. Hypotension or shock
  3. Features of myocardial dysfunction, pericarditis,
    valvulitis, or coronary abnormalities
    (including ECHO findings or elevated Troponin/NT-proBNP)
  4. Evidence of coagulopathy
    (by PT, PTT, elevated d-Dimers)
  5. Acute gastrointestinal problems
    (diarrhoea, vomiting, or abdominal pain)
And
  • Elevated markers of inflammation
    such as ESR, C-reactive protein, or procalcitonin
And
  • No other obvious microbial cause of inflammation,
    including bacterial sepsis,
    staphylococcal or streptococcal shock syndromes
And
  • Evidence of COVID-19
    (RT-PCR, antigen test or serology positive),
    or likely contact with patients with COVID-19

(Note: Consider this syndrome in children with features of
typical or atypical Kawasaki disease
or toxic shock syndrome.)

Diagnosis is by specialist clinical evaluation.[59] Diagnostic suspicion may be raised by unexplained persistent fever and clinically concerning symptoms following exposure to COVID-19.[14] Families need to seek immediate medical care, as the child's condition can deteriorate rapidly.[7] Paediatricians' first involvement is often in the emergency department.[49] Early recognition and multidisciplinary referral to paediatric specialists (in intensive care, infectious diseases, cardiology, haematology, rheumatology, etc.) is essential.[13][23][14][19] Examinations may include blood tests, chest x-ray, heart ultrasound (echocardiography), and abdominal ultrasound.[60] Clinicians worldwide have been urged to consider this condition in children who display some or all the features of Kawasaki disease or toxic shock syndrome.[24]

Case definitions and guidance

[edit]

A universally accepted case definition for this newly described syndrome has still not been agreed.[27][61] In the meantime, different names and provisional case definitions are being used around the world.[27][61] The initial case definitions released by the World Health Organization (WHO), the Royal College of Paediatrics and Child Health (RCPCH) and Centers for Disease Control and Prevention (CDC) all include involvement of more than one organ system, along with fever and elevated inflammatory markers.[43] Criteria that vary among these three definitions include the ways in which involvement of different organs is defined, the duration of fever, and how exposure to COVID-19 is assessed.[15]

  • The preliminary WHO case definition is for "multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19"[2] (box).[24] The WHO has established a platform for standardized, anonymized clinical data, along with a dedicated case report form, and underlines the "urgent need for collection of standardized data describing clinical presentations, severity, outcomes, and epidemiology."[24]
  • Diagnostic guidance by the RCPCH proposes a broader case definition (for PIMS-TS),[27] which was also endorsed by an expert panel convened by the American College of Cardiology.[62] Key clinical criteria set out in the RCPHC case definition are: persistent fever, inflammation (indicated by neutrophilia, high CRP levels and low lymphocyte count), and evidence of organ dysfunction (shock; cardiac, respiratory, renal, gastrointestinal, or neurological disorder), coupled with additional clinical features, including laboratory, imaging and ECG findings.[3][13] Coronary artery abnormalities, such as dilatation, may be apparent at echocardiography and ECG (or contrast CT of the chest).[13] Biomarkers supporting the diagnosis include abnormal fibrinogen levels, high D-dimers (possible coagulopathy), high troponin, low albumin, and high ferritin.[13] According to the RCPCH definition, the child may test positive or negative for SARS-CoV-2, but other possible microbial causes need to be excluded.[3][13]
  • The CDC case definition for MIS-C comprises individuals "aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)."[1] It also requires that there should either be a positive antigen/antibody SARS-CoV-2 test or COVID-19 exposure in the 4 weeks before onset of symptoms, along with exclusion of other plausible diagnoses.[1] This case definition is quite broad (it overlaps not only with Kawasaki disease, but also with juvenile rheumatoid arthritis, and various infectious/inflammatory conditions of childhood, including other viral diseases),[16] but not as broad as the RCPCH definition.[27] The CDC advises health providers in the United States to inform their public health authorities of suspected cases, even if they also meet full or partial criteria for Kawasaki disease, and to consider MIS-C after any childhood fatality in which there is evidence of SARS-CoV-2 infection.[1]

Further case definitions have been formulated by the British Paediatric Surveillance Unit (BPSU) and the Canadian Paediatric Surveillance Program (CPSP).[61] Some provisional diagnostic guidance has been provided by both the American College of Rheumatology[19] and the American Academy of Pediatrics.[14] In the UK, consensus has been reached for diagnostic investigation of children with suspected PIMS-TS.[63] A clinical pathway for diagnostic evaluation of suspected MIS-C has also been proposed by the Children's Hospital of Philadelphia.[59] A set of guidelines proposed by Western New York recommends also evaluating children with clinical features that overlap with the MIS-C case definition, but who have been screened with mild illness and laboratory abnormalities, and who do not have an alternative diagnosis.[21]

Differential diagnosis

[edit]

It is essential to exclude alternative non-infectious[14] and infectious causes of the inflammatory condition, including bacterial sepsis, staphylococcal and streptococcal shock, and infections associated with myocarditis, such as enterovirus.[13][3] (Coinfection with additional pathogens, including human metapneumovirus and various other microbes, may sometimes occur.)[3] Other potentially unrelated sources of abdominal pain include appendicitis and mesenteric adenitis.[64]

Differential diagnosis with Kawasaki disease can be challenging, given the lack of a diagnostic test for either condition.[16] It is not currently known whether the newly described condition is superimposable with Kawasaki disease shock syndrome.[43] Since prompt diagnosis and timely treatment of actual Kawasaki disease is important to prevent complications, a call has been made to "Keep a high suspicion for Kawasaki disease in all children with prolonged fever, but especially in those younger than 1 year of age."[65]

Treatment

[edit]

Due to the limited information available on this rare new diagnosis, clinical management has been largely based on expert opinion, including knowledge acquired from treating Kawasaki disease and other systemic inflammatory disorders of childhood, in addition to experience with COVID-19 in adults.[15] Treatment is tailored for each individual child, with input from the various consulting specialists.[21] Approaches vary.[66] The RCPCH initially outlined a provisional approach to clinical management, including guidance on early medical management, monitoring and some general principles of treatment;[13] for the UK, consensus has since been reached regarding a recommended pathway for clinical management (including access to registered clinical trials).[63] The National Institutes of Health provides some general considerations.[23] The American College of Rheumatology provides guidance for clinical management of MIS-C.[19][6] The American Academy of Pediatrics has also provided some interim guidance.[14] Other proposals have also been made.[15][21][52][66][67] RCPCH guidance recommends that all affected children should be treated as having suspected COVID-19.[13]

Little specific information is available regarding therapeutic effectiveness.[23] Most children who have been treated as for Kawasaki disease have recovered.[7] Supportive care is a mainstay of therapy,[23] and for mild or moderate disease it may be sufficient.[13][20] Major complications may respond well to more aggressive supportive care.[18] Cardiac and respiratory support may benefit children who present predominantly with shock.[21]

Strategies for clinical management tend to be broadly based on anti-inflammatory medications, treatment of shock, and prevention of thrombosis.[66] Most children have received immunomodulatory treatment with intravenous immunoglobulin (IVIG).[68][50][15] IVIG has been reported target IL-1β+ neutrophils and their activation in the affected children.[69] Other anti-inflammatory treatments have been used, including corticosteroids at various doses.[15] Good responses have been recorded for IVIG, with or without corticosteroids.[7][20][32] Cases requiring steroids due to resistance to IVIG may be more common than in Kawasaki disease.[48] In a minority of cases,[7] cytokine blockers have been used as a supplemental therapy to inhibit production of IL-6 (tocilizumab) or IL-1 (anakinra); TNF-α-inhibitors (infliximab) have also been used.[15] Inotropic or vasoactive agents are often used for children with cardiac dysfunction and hypotension.[27] Anticoagulants have been used.[27] Low-dose aspirin has been used as an antiplatelet drug.[15][14][20]

Treatment strategies are being considered to prevent serious long-term complications such as coronary artery aneurysms (the main complication of Kawasaki disease).[38] Close outpatient follow-up by a paediatric cardiology team has been recommended.[15][14]

Causes

[edit]

While it has been hypothesized that the condition is related to COVID-19,[24] it has also been emphasized that the potential link "is neither established nor well understood."[3] A temporal association between SARS-CoV-2 infection and clinical presentation of the syndrome is plausible.[3] A causality assessment found that 'temporality' was among the five (out of nine) Bradford Hill criteria that supported a causal relationship between SARS-CoV-2 infection and the development of the syndrome.[3] Further characterization of the syndrome is essential to identify risk factors and help understand causality.[24] It is unclear to what extent this emerging syndrome has a similar aetiology to Kawasaki disease (a condition predating the emergence of SARS-CoV-2, which is currently thought to be triggered by a distinct viral agent).[16] Although some cases resemble toxic shock syndrome, there is no evidence that staphylococcal or streptococcal toxins are involved.[27] The role of comorbidities is unclear.[15] Improved understanding will have potential implications for clinical management.[70] Genome-wide association studies are expected to provide insights on susceptibility and potential biological mechanisms.[48]

Mechanism

[edit]

The pathogenesis is not completely known and could implicate several factors.[50][1][3] SARS-CoV-2 could have one of several roles; it could act as an environmental trigger for the condition either directly or indirectly (by somehow paving the way for a different trigger).[45]

As with Kawasaki disease, antibody-dependent enhancement, whereby development of antibodies could facilitate viral entry into host cells, has been proposed as a potential mechanism.[3][71] Epidemiological considerations make a post-infectious mechanism seem likely,[50][20][22][16][72] possibly coinciding with the development of acquired immune responses to the virus.[27] It has been suggested that the condition may be caused by the cytokine storms induced by COVID-19.[17][72] The characteristic ability of coronaviruses to block type I and type III interferon responses could help explain a delayed cytokine storm in children whose immune systems struggle to control SARS-CoV-2 viral replication, or are overwhelmed by a high initial viral load.[16] One plausible chain of events leading up to a hyperimmune response could involve early viral triggering of macrophage activation, followed by T helper cell stimulation, in turn leading to cytokine release, stimulation of macrophages, neutrophils, and monocytes, in conjunction with B cell and plasma cell activation, and autoantibody production.[50][32]

It is unknown to what extent the pathophysiology resembles that of other paediatric inflammatory syndromes that share similar clinical features.[71] Clinical overlaps with syndromes that have different causes (Kawasaki disease, toxic shock, macrophage activation syndrome, and secondary haemophagocytic lymphohistiocytosis) may be explained by immunological activation and dysregulation of similar inflammatory pathways.[50][73] In each of these syndromes, a cytokine storm leads to failure of multiple organs.[49] They also share with MIS-C and severe cases of COVID-19 high levels both of ferritin (released by neutrophils) and of haemophagocytosis.[49]

The frequent gastrointestinal presentation and mesenteric lymph node inflammation are in keeping with the known liking of SARS-CoV-2 to replicate in enterocytes.[16] Association of Kawasaki-like disease with COVID-19 could support the view that SARS-CoV-2 can cause systemic vasculitis by targeting endothelial tissue via angiotensin-converting enzyme 2 (ACE2), the protein which the virus uses to gain access to cells.[74] While the initial infection is known to be capable of causing acute myocardial damage, occurrence of myocarditis could also plausibly be linked to systemic hyperinflammation triggered by a disorderly post-infectious immune response.[15] It has been suggested that SARS-CoV-2 might lead to immune-mediated damage to the heart and coronary arteries via immune complexes or increased T-cell responses.[27]

Understanding the pathophysiology is a key research priority.[75] Questions regarding the underlying molecular mechanisms that lead to the disorder following exposure to SARS-CoV-2 include identification of: any genetic predisposition factors; any associations with particular viral variant/s; any molecular patterns capable of triggering the autoimmune/autoinflammatory responses.[48] Another key question is whether the molecular mechanisms that trigger autoimmune/autoinflammatory responses in children with PMIS and adults with severe COVID-19 (including the induction of high concentrations of IL-6) are similar or distinct.[48]

A potential link with Kawasaki disease is under discussion.[76] It has been noted that a leading hypothesis for the pathogenesis of Kawasaki disease also involves a hyperinflammatory response to viral infection (such as by a novel RNA virus[47][77]) in some genetically predisposed children, and that SARS-CoV-2 is now "added to the list" of implicated viral triggers.[48] Hopes have been expressed that study of the new condition may help understand the hidden mechanisms behind Kawasaki disease.[38] But current evidence suggest that MIS-C and Kawasaki disease represent two distinct disease entities[50]

Proposed role of the STING pathway

[edit]

A possible role of the stimulator of interferon genes known as STING has been proposed.[5] SARS-CoV-2 is capable of upregulating the STING protein (encoded by TMEM173 transmembrane protein, and expressed in alveoli, endothelial cells, and the spleen), resulting in massive release of interferon-beta and cytokines derived from activation of NF-κB and IRF-3.[5] In MIS-C, such a scenario could lead to a clinical picture similar to STING-associated vasculopathy with onset in infancy (also known as SAVI) – a condition characterized by fever, lung injury, vascular inflammation, myositis, skin lesions (occasionally acral necrosis), and arterial aneurysms.[5] Variations in the presentation and severity of MIS-C might at least partially be explained by characteristic differences in polymorphisms of TMEM173 found in various populations.[5]

Epidemiology

[edit]

Epidemiological information is limited, and clinical statistics currently derive from review of case series.[6][22][a] This emerging condition is considered rare.[3] Its incidence is not known.[6][56][b] Based on available reports, the fatality rate among diagnosed cases appears to have been about 1.7% (notably higher than the rate of 0.07% recorded among children with Kawasaki disease in Japan).[7] A rapid risk assessment conducted by the European Centre for Disease Prevention and Control (ECDC) concluded that the overall risk to children in the European Union (EU), European Economic Area (EEA) and the UK "is considered 'low', based on a 'very low' probability of [the disease] in children and a 'high' impact of such disease."[3]

Clusters of cases of the newly described condition have been recorded 3–4 weeks after peaks in SARS-CoV-2 viral transmission through various local communities.[20][c] Such observations have been seen to support the concept that SARS-CoV-2 infection may be capable of triggering a severe form of a Kawasaki-like disease.[77] Frequent presentation without prominent respiratory symptoms in children who do not appear to have ongoing SARS-CoV-2 infection but who have already developed antibodies suggests that the disease may be driven by a delayed, post-infectious mechanism.[20]

The median age of onset appears to be at least 7 years (compared with 2 years for Kawasaki disease, which primarily affects children under the age of 5).[22] Male children seem to be more frequently affected (broadly in line with Kawasaki disease, where the male to female ratio is about 1.5 to 1).[22] Many affected children appear not to have underlying health conditions, such as asthma or autoimmune disorders, and there have been relatively few reports of known congenital heart disease or preexisting cardiovascular disease.[7][15] Over half (52%) the children with available information had no recorded underlying health condition, including being overweight or obese (among those who did have some comorbidity, 51% were either overweight or obese).[7]

Regarding ethnicity, reports from France and the UK raised the possibility that children of Afro-Caribbean descent may be at greater risk, plausibly due to a genetic predisposition.[48] In the US (as of mid-July), the majority of cases were classified as Hispanic/Latino (38%) or non-Hispanic Black (33%) people.[83] Based on reports confined to Europe and the US, the condition seems to affect more children of African, Afro-Caribbean, and Hispanic descent, whereas Kawasaki disease affects more of East Asian and Pacific Islander ancestry.[19][76] The role of socioeconomic and other environmental factors in such discrepancies is unclear.[45] One study suggested that rates of children with COVID-19 who do not get MIS-C may be underrepresented in some communities and lack diversity, making it difficult to determine the rates of MIS-C among children who were infected with COVID-19 in these communities.[84]

As regards geographical distribution, there has been uncertainty as to whether the initial reports of cases in Europe and North America reflected a true pattern, or whether the condition had gone unrecognized elsewhere.[3][24] In Japan and other Southeast and East Asian countries where Kawasaki disease is usually much more prevalent than in Europe, no case of Kawasaki-like disease linked to COVID-19 had been reported during the first wave of transmission.[3][16][77][85][d] Reports of confirmed or suspected cases have since emerged in many different countries around the world.[27][e]

None of the three main provisional case-definitions of the emerging entity is diagnostically specific.[76] Concerns have been raised regarding the potential for missed or delayed diagnosis of Kawasaki disease due to heightened diagnostic suspicion for the new entity.[65] Misclassification of cases of Kawasaki disease and of other inflammatory and infectious diseases of childhood whose case definitions overlap with MIS-C could skew understanding of the new entity, such as the frequency of coronary artery aneurysms.[105][106] Another concern is that clinically less severe cases of the new entity may be missed, and that the actual spectrum of disease severity could be broader,[27][107] especially given the reliance on early observations of severe disease for provisional case definition.[108] Some statistical modeling has been used to explore possible subdivision of cases satisfying the CDC's case definition into three distinct subgroups based on underlying clinical similarities: Class 1, characterized by pronounced multiorgan involvement, with little overlap with Kawasaki disease or acute COVID-19; Class 2, more predominantly characterized by respiratory symptoms typical of acute COVID-19; Class 3, a clinically less severe grouping, where rashes and mucosal symptoms are prevalent, with less multiorgan involvement, and generally greater overlap with Kawasaki disease.[109][58] A suggestion[108] that research into the biology of the disease might benefit from considering cases of Kawasaki disease and of the provisionally defined entity in conjunction is debated.[109]

In adults

[edit]

There has been uncertainty as to whether the condition is confined to children,[21] and the appropriateness of excluding adults from case definitions has been questioned.[110] Sporadic reports exist of a similar life-threatening condition, denominated 'multisystem inflammatory syndrome in adults' (MIS-A), which also usually requires intensive care.[29]

History

[edit]

Cases of Kawasaki disease with concurrent SARS-CoV-2 infection have been recorded among children in Europe and in the United States since 7 April 2020, when a report was published by the American Academy of Pediatrics regarding a case of 'classic' Kawasaki disease in a six-month old girl who tested positive for COVID-19 in California.[3][111] In this case, COVID-19 did not appear to have significant clinical implications.[70][111]

On 25 April, concerns were initially raised in the United Kingdom regarding a cluster of children of various ages presenting with a multisystem inflammatory state who required intensive care, and who all displayed "overlapping features of toxic shock syndrome and atypical Kawasaki disease with blood parameters consistent with severe COVID-19 in children."[38][112] Details of the eight cases which helped trigger this alert (not all with confirmed exposure to COVID-19) were later reported in The Lancet, where the authors summarized the clinical picture as "a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome."[70][113] Accounts of analogous cases – including some that appeared less clinically severe – were also being informally shared among clinicians around Europe.[38] The EU's Early Warning and Response System flagged suspected cases in Austria, Germany and Portugal that had tested positive for SARS-CoV-2.[3] In Bergamo, at the heart of the COVID-19 epidemic in Lombardy, a cluster of 20 cases of Kawasaki disease appeared to be roughly equivalent to the number commonly recorded there over the course of three years.[70] In France, the government reported on 29 April that around 15 children were in hospital in Paris with symptoms of Kawasaki disease,[70][114] an observation which prompted the organization of national surveillance programme for recent cases of Kawasaki-like disease.[79]

On 1 May, the RCPCH published a preliminary case definition based on review of the characteristics of the cases identified in the UK, accompanied by some clinical guidance.[13][38] Two weeks later, on 15 May, two further preliminary case definitions were published separately by the WHO[24] and by the CDC,[1] while the ECDC released a 'rapid risk assessment' of the condition on behalf of the European Union.[3] In the following weeks, further clinical guidance was released by other medical organizations, including the NIH,[23] the American College of Rheumatology,[25] and the American Academy of Pediatrics.[26] On 4 May, the New York City Department of Health and Mental Hygiene issued an alert to identify children with the condition in New York City hospitals,[3] where 15 such cases were already being treated.[115] On 9 May, the governor of New York, Andrew Cuomo announced a collaboration with the CDC to help develop national criteria for identifying and responding to the newly identified childhood disease.[116]

By 12 May, some 230 suspected cases had been reported across the EU and EEA, and in the UK[3] (in the following days, sources were reporting up to 100 in the UK,[117] over 135 in France,[118] 20 in the Netherlands,[119] 10 in Switzerland[120] and 10 in Germany[121]). In the United States, more than 200 cases were suspected by mid-May,[122] including some 145 in New York;[123][124] 186 confirmed cases were eventually diagnosed between 15 March and 20 May in 26 US states.[125][126] As of 11 May 2020, five fatalities were reported (1 in France, 1 in the UK, 3 in the US).[3] In peer-reviewed medical journals, case series and related studies of the new condition were rapidly reported from countries including the UK;[127][128] Italy;[80] Spain;[129][130][131] France and Switzerland;[132] France;[4][133][134] and across the US,[125][135] including New York.[78][136][137] The emerging observations suggested somewhat greater variety in the severity of symptoms than was originally thought.[23] The proposal of a new clinical entity during a pandemic also prompted scientific discussion about its possible distinction from Kawasaki disease, and the potential role of COVID-19.[38][61][70][76][77][85][106][108]

By 15 July 342 confirmed MIS-C cases (including 6 deaths) had been recorded in the US across 36 states plus Washington DC.[83][138] Most (71%) of the children were Hispanic/Latino or non-Hispanic Black people, and the CDC underlined the need to learn the reasons for such a preponderance.[83][139] By 29 July, a total of 570 cases and 10 deaths had been reported across 40 states, Washington DC, and New York City.[58]

Until late May, no confirmed case had been documented outside the EU/EEA/UK and USA.[3] No suspicious case had been observed in East Asia or Southeast Asia (or in Australia or New Zealand).[85][140][141] The absence of documented cases in China and other Asian countries that had already experienced a COVID-19 epidemic led to conjectures regarding the possibility of a significant evolution of the virus, or variations in susceptibility in different populations.[32] On 2 June, news emerged of a first case of MIS-C diagnosed in Peru.[142][143] In Brazil, cases of MIS-C have been reported in São Paulo,[144] and in the context of a prospective study in Pará;[145] more children with severe late manifestations of COVID-19 were being admitted to paediatric intensive care units in the region.[145] In Chile, 42 confirmed cases of MIS-C had been recorded nationally by 28 June, including 27 in the capital, Santiago.[146] In Russia, 13 children had been treated (5 with intensive care) by mid-June for a multisystem inflammatory syndrome at the Morozov Children's Hospital in Moscow, including a 2-year-old girl with the COVID-19 infection who died on 23 May following an initial diagnosis of suspected Kawasaki disease.[90] In Iran, a case report (first submitted in May) described severe MIS-C in a 5-year-old girl who had presented with shock and was initially diagnosed with Kawasaki disease,[97] and further cases of the new syndrome have been recorded.[98] In India, a case of suspected MIS-C was reported in late May regarding a child who had presented in a COVID-19 hotspot in Kerala.[92] An editorial commentary urged clinicians to have a high level of diagnostic suspicion and follow WHO and CDC definitions to facilitate timely identification and treatment of cases.[147]

During July, suspected cases were being flagged and reported in Mumbai,[148] in Delhi,[149] Chennai,[91] and elsewhere.[150] In Pakistan,[151] at least 24 children were said to have Kawasaki-like symptoms in Lahore,[152] where 8 cases fulfilling WHO criteria were prospectively identified by 30 June.[93] In Kazakhstan, 14 cases were confirmed by 20 August (among 2,357 children known to have been infected).[94] Cases have been recorded in Israel,[100] including one of a child who presented with severe central nervous system involvement and complement deficiency.[101] In Turkey, four children with a Kawasaki-like disease probably associated with COVID-19 are reported to have been admitted to the children's hospital of Hacettepe University in Ankara between 13 April and 11 July.[96] In Algeria, a first case was recorded in June.[102] In Egypt, on 10 July the authorities denied rumours of the existence of cases of Kawasaki-like disease in the country.[153] In South Africa, the first 23 affected children were treated in Cape Town – the initial epicentre of the national COVID-19 epidemic – between 4 June and 24 July.[103] In Ecuador, the Ministry of Health announced on 19 July the presence of 46 probable cases.[154] In Costa Rica, a national public health organization announced towards the end of August that three children had been diagnosed with MIS-C.[155] Cases of MIS-C had also been recorded in many other Latin American countries, including Argentina, Bolivia, Colombia, Cuba, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Uruguay, and Venezuela, as well as in Puerto Rico.[28] News of a first confirmed case of PIMS-TS in Australia emerged (from Victoria) on 4 September, along with news of other suspected cases under review.[156] In South Korea, news of two confirmed cases broke on 5 October[95] (and the existence of a case dating back to the end of April was reported in November[87]).

A similar condition began to be recognized in some adults.[110][29][157] In June, an adult case of a Kawasaki-like multisystem inflammatory syndrome following SARS-CoV-2 infection was described in a 54-year-old woman from Israel with no history of autoimmune disease, who experienced uveitis in both eyes.[158] (A further suspected adult case was covered in the Israeli national press.)[159] A case involving a 36-year-old Hispanic American woman with clinical features otherwise consistent with MIS-C was reported from New York.[160] A diagnosis consistent with PMIS was also reported in a UK-born, 21-year-old man of Somali origin.[161] A case report published in The Lancet regarding a 45-year-old Hispanic man who presented in New York with features strongly resembling MIS-C called for awareness of "a potential MIS-C-like condition in adults."[162] Further reports of multisystem inflammatory syndrome linked to COVID-19 exposure emerged in adults.[157][163][164][165][166] In October, the CDC reported on the condition and named it 'multisystem inflammatory syndrome in adults' (MIS-A).[29] Questions have been raised regarding possible relationships between MIS-C and certain severe manifestations of COVID-19 in adults.[110]

Children's neurological symptoms, as studied in London in mid-2020, often involved "both the central and peripheral nervous systems," according to a report by the American Academy of Neurology released on 13 April 2021.[167][168]

Explanatory notes

[edit]
  1. ^ Given that hospital case series can be selected on the basis of clinical factors such as presence of heart failure or admission to intensive care units, available statistical information regarding the frequencies of different clinical features may be skewed by selection bias.[56]
  2. ^ In the state of New York, about 2 out of 100,000 individuals under 21 years of age are thought to have been affected in conjunction with the COVID-19 epidemic there (with the numbers of new cases peaking 31 days after the local peak in viral infection).[6][78]
  3. ^ A nationwide surveillance programme in France, set up to investigate the temporal relationship between SARS-CoV-2 infection and PMIS, revealed that 95 of the 156 cases of Kawasaki-like disease notified between 1 March and 17 May 2020 were "confirmed or probable post-COVID-19 cases", with a peak in incidence 4–5 weeks after the peak of the COVID-19 epidemic in the country.[79] Clinicians in Bergamo, Italy, reported an apparent (not seasonally adjusted[15]) 30-fold increase in the incidence of Kawasaki-like disease during the first six weeks after the arrival there of SARS-CoV-2 virus infection, at a time when Bergamo was experiencing the highest rates of infections and deaths in Italy.[38][80] In the UK, the number of intensive care admissions for children fulfilling the RCPCH case definition of PMIS during 40 days through April and early May, following the first national surge in COVID-19 cases, was at least 11-fold higher than historical trends for paediatric inflammatory conditions.[81] Time series analysis of cases of Kawasaki disease admitted to a paediatric centre in Paris, France, revealed a spike that started 2 weeks after the first peak of the COVID-19 epidemic there, corresponding to a roughly 5-fold increase in incidence.[82] These cases from Paris had a similarly severe clinical profile to those reported in Bergamo (and differed from the more typical Kawasaki disease profile observed in a newly uncovered spike following the peak of the 2009 H1N1 swine flu epidemic in Paris).[82]
  4. ^ No apparent rise in new cases of Kawasaki disease was noted in these countries,[48] including in South Korea[86] (where one diagnosis was subsequently reclassified as MIS-C[87]), and in Singapore.[88] There had been no report of Kawasaki disease or Kawasaki-like symptoms in mainland China.[89]
  5. ^ An extensive Latin-American Kawasaki disease surveillance network (REKAM-LATINA) has recorded cases of MIS-C across all its participating countries.[28] Some other countries where cases have been reported include Russia,[90] India,[91][92] Pakistan,[93] Kazakhstan,[94] South Korea,[87][95] Turkey,[96] Iran,[97][98] Saudi Arabia,[99] Israel,[100][101] Algeria,[102] South Africa,[103] and Australia.[104]

References

[edit]
  1. ^ a b c d e f g h i "Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)". emergency.cdc.gov. Centers for Disease Control and Prevention. 14 May 2020. Archived from the original on 15 May 2020.
  2. ^ a b c "Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19". www.who.int. World Health Organization. Archived from the original on 24 June 2020.
  3. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af "Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children" (PDF). European Centre for Disease Prevention and Control. 15 May 2020. Archived from the original on 15 May 2020.
  4. ^ a b c Pouletty M, Borocco C, Ouldali N, et al. (June 2020). "Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort". Annals of the Rheumatic Diseases. 79 (8): 999–1006. doi:10.1136/annrheumdis-2020-217960. PMC 7299653. PMID 32527868. S2CID 219607184.
  5. ^ a b c d e f Dhar D, Dey T, Samim MM, et al. (2021). "Systemic inflammatory syndrome in COVID-19-SISCoV study: systematic review and meta-analysis". Pediatric Research. 91 (6): 1334–1349. doi:10.1038/s41390-021-01545-z. PMC 8128982. PMID 34006982.
  6. ^ a b c d e f g h i j k l m n o p q Henderson LA, Canna SW, Friedman KG, et al. (July 2020). "American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 1". Arthritis & Rheumatology. 72 (11): 1791–1805. doi:10.1002/art.41454. PMC 7405113. PMID 32705809.
  7. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al Ahmed M, Advani S, Moreira A, et al. (September 2020). "Multisystem inflammatory syndrome in children: a systematic review". eClinicalMedicine. 26: 100527. doi:10.1016/j.eclinm.2020.100527. ISSN 2589-5370. PMC 7473262. PMID 32923992. S2CID 221494176.
  8. ^ "Multisystem Inflammatory Syndrome in Children (MIS-C): Information for Healthcare Providers About Talking with Families and Caregivers". Centers for Disease Control. Retrieved 3 June 2024.
  9. ^ Payne, Amanda B.; Gilani, Zunera; Godfred-Cato, Shana (2021). "Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2". JAMA Netw Open. doi:10.1001/jamanetworkopen.2021.16420. PMC 8193431.
  10. ^ Zhang M, Zhang P, Liang Y, et al. (2022). "A systematic review of current status and challenges of vaccinating children against SARS-CoV-2". Journal of Infection and Public Health. 15 (11): 1212–1224. doi:10.1016/j.jiph.2022.10.006. PMC 9557115. PMID 36257126.
  11. ^ "Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to January 30, 2022" (PDF). Public Health Ontario. Retrieved 11 February 2022.
  12. ^ Jain, Eisha; Donowitz, Jeffrey R.; Aarons, Elizabeth; Marshall, Beth C.; Miller, Michael P. (May 2022). "Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination". Emerging Infectious Diseases. 28 (5): 990–993. doi:10.3201/eid2805.212418. PMC 9045439. PMID 35275051.
  13. ^ a b c d e f g h i j k l m n o p q "Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS)". RCPCH. Royal College of Paediatrics and Child Health. May 2020. Archived from the original on 16 June 2020.
  14. ^ a b c d e f g h i j k l m n o p q "Multisystem inflammatory syndrome in children (MIS-C) interim guidance". services.aap.org. American Academy of Pediatrics. July 2020. Archived from the original on 17 July 2020.
  15. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad Sperotto F, Friedman KG, Son MB, et al. (2020). "Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach". European Journal of Pediatrics. 180 (2): 307–322. doi:10.1007/s00431-020-03766-6. PMC 7429125. PMID 32803422.
  16. ^ a b c d e f g h i j k Rowley AH (June 2020). "Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children". Nature Reviews. Immunology. 20 (8): 453–454. doi:10.1038/s41577-020-0367-5. PMC 7296515. PMID 32546853.
  17. ^ a b Alunno A, Carubbi F, Rodríguez-Carrio J (2020). "Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin". RMD Open. 6 (1): e001295. doi:10.1136/rmdopen-2020-001295. PMC 7299508. PMID 32423970.
  18. ^ a b c d e Aronoff SC, Hall A, Del Vecchio MT (September 2020). "The natural history of SARS-Cov-2 related multisystem inflammatory syndrome in children (MIS-C): a systematic review". Journal of the Pediatric Infectious Diseases Society. 9 (6): 746–751. doi:10.1093/jpids/piaa112. PMC 7797745. PMID 32924059.
  19. ^ a b c d e f g h ACR MIS-C and COVID-19 Related Hyperinflammation Task Force (17 June 2020). "Clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19" (PDF). rheumatology.org. American College of Rheumatology. Archived (PDF) from the original on 25 June 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)
  20. ^ a b c d e f g h i j k l m n o p Rajapakse N, Dixit D (June 2020). "Human and novel coronavirus infections in children: a review". Paediatrics and International Child Health. 41 (1): 36–55. doi:10.1080/20469047.2020.1781356. PMID 32584199. S2CID 220061129.
  21. ^ a b c d e f g Hennon TR, Penque MD, Abdul-Aziz R, et al. (May 2020). "COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach". Progress in Pediatric Cardiology. 57: 101232. doi:10.1016/j.ppedcard.2020.101232. PMC 7244417. PMID 32837142.
  22. ^ a b c d e f g h i j k l Abrams JY, Godfred-Cato SE, Oster ME, et al. (August 2020). "Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: a systematic review". The Journal of Pediatrics. 226: 45–54.e1. doi:10.1016/j.jpeds.2020.08.003. PMC 7403869. PMID 32768466.
  23. ^ a b c d e f g h i "Special Considerations in Children". NIH - COVID-19 Treatment Guidelines. National Institutes of Health. 11 June 2020. Archived from the original on 19 July 2020.
  24. ^ a b c d e f g h i j "Multisystem inflammatory syndrome in children and adolescents with COVID-19: scientific brief". www.who.int. World Health Organization. Archived from the original on 15 May 2020.
  25. ^ a b Pond, E (20 July 2020). "ACR guidelines for the management of pediatric multisystem inflammatory syndrome associated with SARS-CoV-2". Rheumatology Advisor. Archived from the original on 21 July 2020.
  26. ^ a b Hester, M (21 July 2020). "AAP issues interim guidance for MIS-C". Contemporary Pediatrics. Archived from the original on 21 July 2020.
  27. ^ a b c d e f g h i j k l Jiang L, Tang K, Levin M, et al. (August 2020). "COVID-19 and multisystem inflammatory syndrome in children and adolescents". Lancet Infectious Diseases. 20 (11): e276 – e288. doi:10.1016/S1473-3099(20)30651-4. PMC 7431129. PMID 32818434.
  28. ^ a b c Ulloa-Gutierrez R, Ivankovich-Escoto G, Yock-Corrales A, Tremoulet AH (September 2020). "Multisystem inflammatory syndrome (MIS-C) surveillance and COVID-19 in Latin America". The Pediatric Infectious Disease Journal. 39 (12): e473 – e474. doi:10.1097/INF.0000000000002901. PMID 32947601.
  29. ^ a b c d Morris SB, Schwartz NG, Patel P, et al. (October 2020). "Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, March-August 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (40): 1450–1456. doi:10.15585/mmwr.mm6940e1. PMC 7561225. PMID 33031361.
  30. ^ Lu X, Zhang L, Du H, et al. (April 2020). "SARS-CoV-2 infection in children". The New England Journal of Medicine. 382 (17): 1663–1665. doi:10.1056/NEJMc2005073. PMC 7121177. PMID 32187458.
  31. ^ Zimmermann P, Curtis N (May 2020). "Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children". The Pediatric Infectious Disease Journal. 39 (5): 355–368. doi:10.1097/INF.0000000000002660. PMC 7158880. PMID 32310621.
  32. ^ a b c d e f g h Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S (July 2020). "Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management". Children. 7 (7): 69. doi:10.3390/children7070069. PMC 7401880. PMID 32630212.
  33. ^ a b Hoang A, Chorath K, Moreira A, et al. (July 2020). "COVID-19 in 7780 pediatric patients: a systematic review". eClinicalMedicine. 24: 100433. doi:10.1016/j.eclinm.2020.100433. PMC 7318942. PMID 32766542.
  34. ^ a b Yasuhara J, Kuno T, Takagi H, Sumitomo N (July 2020). "Clinical characteristics of COVID-19 in children: a systematic review". Pediatric Pulmonology. 55 (10): 2565–2575. doi:10.1002/ppul.24991. PMID 32725955.
  35. ^ Jeng MJ (June 2020). "Coronavirus disease 2019 in children: current status". Journal of the Chinese Medical Association. 83 (6): 527–533. doi:10.1097/JCMA.0000000000000323. PMC 7199766. PMID 32502117.
  36. ^ Choi SH, Kim HW, Kang JM, et al. (April 2020). "Epidemiology and clinical features of coronavirus disease 2019 in children". Clinical and Experimental Pediatrics. 63 (4): 125–132. doi:10.3345/cep.2020.00535. PMC 7170785. PMID 32252139.
  37. ^ Castagnoli R, Votto M, Licari A, et al. (April 2020). "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review". JAMA Pediatrics. 174 (9): 882–889. doi:10.1001/jamapediatrics.2020.1467. PMID 32320004.
  38. ^ a b c d e f g h i Viner RM, Whittaker E (2020). "Kawasaki-like disease: emerging complication during the COVID-19 pandemic". The Lancet. 395 (10239): 1741–1743. doi:10.1016/S0140-6736(20)31129-6. PMC 7220168. PMID 32410759.
  39. ^ Wolff AE, Hansen KE, Zakowski L (May 2007). "Acute Kawasaki disease: not just for kids". Journal of General Internal Medicine. 22 (5): 681–4. doi:10.1007/s11606-006-0100-5. PMC 1852903. PMID 17443379.
  40. ^ a b Dietz SM, van Stijn D, Burgner D, et al. (2017). "Dissecting Kawasaki disease: a state-of-the-art review". European Journal of Pediatrics. 176 (8): 995–1009. doi:10.1007/s00431-017-2937-5. PMC 5511310. PMID 28656474.
  41. ^ "Kawasaki Disease". PubMed Health. NHLBI Health Topics. 11 June 2014. Archived from the original on 11 September 2017. Retrieved 26 August 2016.
  42. ^ Brogan P, Burns JC, Cornish J, et al. (2020). "Lifetime cardiovascular management of patients with previous Kawasaki disease". Heart. 106 (6): 411–420. doi:10.1136/heartjnl-2019-315925. PMC 7057818. PMID 31843876.
  43. ^ a b c d Walker DM, Tolentino VR (June 2020). "COVID-19: The impact on pediatric emergency care". Pediatric Emergency Medicine Practice. 17 (Suppl 6-1): 1–27. PMID 32496723.
  44. ^ Taddio A, Rossi ED, Monasta L, et al. (2017). "Describing Kawasaki shock syndrome: results from a retrospective study and literature review". Clinical Rheumatology. 36 (1): 223–228. doi:10.1007/s10067-016-3316-8. PMID 27230223. S2CID 1104479.
  45. ^ a b c McCrindle BW, Manlhiot C (2020). "SARS-CoV-2-related inflammatory multisystem syndrome in children: different or shared etiology and pathophysiology as Kawasaki disease?". JAMA. 324 (3): 246–248. doi:10.1001/jama.2020.10370. PMID 32511667. S2CID 219553490.
  46. ^ Marrani E, Burns JC, Cimaz R (2018). "How should we classify Kawasaki disease?". Frontiers in Immunology. 9: 2974. doi:10.3389/fimmu.2018.02974. PMC 6302019. PMID 30619331.
  47. ^ a b c McCrindle BW, Rowley AH, Newburger JW, et al. (2017). "Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association". Circulation. 135 (17): e927 – e999. doi:10.1161/CIR.0000000000000484. PMID 28356445.
  48. ^ a b c d e f g h i Galeotti C, Bayry J (2020). "Autoimmune and inflammatory diseases following COVID-19". Nature Reviews. Rheumatology. 16 (8): 413–414. doi:10.1038/s41584-020-0448-7. PMC 7271827. PMID 32499548.
  49. ^ a b c d e f g h Junior HS, Sakano TM, Rodrigues RM, et al. (September 2020). "Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view". Jornal de Pediatria. 97 (2): 140–159. doi:10.1016/j.jped.2020.08.004. PMC 7486073. PMID 32946801.
  50. ^ a b c d e f g h Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, Singh-Grewal D, Bharath S, Sajjan S, Bayry J (29 October 2021). "Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison". Nat Rev Rheumatol. 17 (12): 731–748. doi:10.1038/s41584-021-00709-9. PMC 8554518. PMID 34716418.
  51. ^ Kaya G, Kaya A, Saurat JH (June 2020). "Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature". Dermatopathology. 7 (1): 3–16. doi:10.3390/dermatopathology7010002. PMC 7583593. PMID 32608380.
  52. ^ a b Kache S, Chisti MJ, Gumbo F, et al. (July 2020). "COVID-19 PICU guidelines: for high- and limited-resource settings". Pediatric Research. 88 (5): 705–716. doi:10.1038/s41390-020-1053-9. PMC 7577838. PMID 32634818.
  53. ^ Chen TH (August 2020). "Neurological involvement associated with COVID-19 infection in children". Journal of the Neurological Sciences. 418: 117096. doi:10.1016/j.jns.2020.117096. PMC 7423535. PMID 32823135.
  54. ^ a b Divani AA, Andalib S, Biller J, et al. (2020). "Central Nervous System Manifestations Associated with COVID-19". Current Neurology and Neuroscience Reports. 20 (12): 60. doi:10.1007/s11910-020-01079-7. PMC 7599061. PMID 33128130.
  55. ^ a b Rodríguez Y, Novelli L, Rojas M, et al. (June 2020). "Autoinflammatory and autoimmune conditions at the crossroad of COVID-19". Journal of Autoimmunity. 114: 102506. doi:10.1016/j.jaut.2020.102506. PMC 7296326. PMID 32563547.
  56. ^ a b c d e Alsaied T, Tremoulet AH, Burns JC, et al. (November 2020). "Review of cardiac involvement in multisystem inflammatory syndrome in children". Circulation. 143 (1): 78–88. doi:10.1161/CIRCULATIONAHA.120.049836. PMID 33166178.
  57. ^ a b Tonge J, Stevens O, et al. (2021). "Assessing the Response of Biomarkers to Anti-Inflammatory Medications in PIMS-TS by Longitudinal Multilevel Modeling: Real-World Data from a UK Tertiary Center". Pediatric Allergy, Immunology, and Pulmonology. 36 (3): 94–103. doi:10.1089/ped.2023.0024. PMID 37433192. S2CID 259832603.
  58. ^ a b c Godfred-Cato S, Bryant B, Leung J, et al. (August 2020). "COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (32): 1074–1080. doi:10.15585/mmwr.mm6932e2. PMC 7440126. PMID 32790663.
  59. ^ a b "Multisystem inflammatory syndrome (MIS-C) clinical pathway – emergency, ICU and inpatient". www.chop.edu. The Children's Hospital of Philadelphia. 20 May 2020. Archived from the original on 26 June 2020.
  60. ^ "For parents: multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19". cdc.com. Centers for Disease Control and Prevention. 20 May 2020. Archived from the original on 1 September 2020.
  61. ^ a b c d Kanthimathinathan HK, Scholefield BR (September 2020). "Pediatric inflammatory multisystem syndrome: time to collaborate". Journal of the Pediatric Infectious Diseases Society. 10 (3): 227–229. doi:10.1093/jpids/piaa105. PMC 7543404. PMID 32945863.
  62. ^ Newburger, JW (15 May 2020). "Pediatric hyperinflammatory syndrome and COVID-19: statement and recommendations from a pediatric intensive care international collaborative conference call". www.acc.org. American College of Cardiology. Archived from the original on 19 May 2020.
  63. ^ a b Harwood R, Allin B, Jones CE, et al. (September 2020). "A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process". The Lancet Child & Adolescent Health. 5 (2): 133–141. doi:10.1016/S2352-4642(20)30304-7. ISSN 2352-4642. PMC 7500943. PMID 32956615.
  64. ^ Harwood R, Partridge R, Minford J, Almond S (September 2020). "Paediatric abdominal pain in the time of COVID-19: a new diagnostic dilemma". Journal of Surgical Case Reports. 2020 (9): rjaa337. doi:10.1093/jscr/rjaa337. PMC 7505408. PMID 32994918.
  65. ^ a b Harahsheh AS, Dahdah N, Newburger JW, et al. (May 2020). "Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic". The Journal of Pediatrics. 222: 261–262. doi:10.1016/j.jpeds.2020.04.052. PMC 7196408. PMID 32370951.
  66. ^ a b c Elias MD, McCrindle BW, Larios G, et al. (September 2020). "Management of multisystem inflammatory syndrome in children associated with COVID-19: a survey from the International Kawasaki Disease Registry". CJC Open. 2 (6): 632–640. doi:10.1016/j.cjco.2020.09.004. PMC 7484693. PMID 32935083.
  67. ^ García-Salido A, Antón J, Martínez-Pajares JD, et al. (October 2020). "[Spanish consensus document on diagnosis, stabilisation and treatment of pediatric multisystem inflammatory syndrome related to SARS-CoV-2 (SIM-PedS)]". Anales de Pediatria (in European Spanish). 94 (2): 116.e1–116.e11. doi:10.1016/j.anpedi.2020.09.005. PMC 7604157. PMID 33132066.
  68. ^ Zhu YP, Shamie I, Lee JC, Nowell CJ, Peng W, Angulo S, Le LN, Liu Y, Miao H, Xiong H, Pena CJ, Moreno E, Griffis E, Labou SG, Franco A, Broderick L, Hoffman HM, Shimizu C, Lewis NE, Kanegaye JT, Tremoulet AH, Burns JC, Croker BA, et al. (Pediatric Emergency Medicine Kawasaki Disease Research Group Consortium) (15 October 2021). "Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C". J Clin Invest. 131 (20): e147076. doi:10.1172/JCI147076. PMC 8516453. PMID 34464357. Retrieved 3 December 2021.
  69. ^ Ganigara M, Sharma C, Bayry J (October 2021). "Unraveling the mechanisms of IVIG immunotherapy in MIS-C". Cell Rep Med. 2 (10): 100431. doi:10.1016/j.xcrm.2021.100431. PMC 8481087. PMID 34608458.
  70. ^ a b c d e f Schroeder AR, Wilson KM, Ralston SL (2020). "COVID-19 and Kawasaki disease: finding the signal in the noise" (PDF). Hospital Pediatrics. 10 (10): e1 – e3. doi:10.1542/hpeds.2020-000356. PMID 32404331. S2CID 218634534.
  71. ^ a b Tanner T, Wahezi DM (July 2020). "Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19". Paediatric Respiratory Reviews. 35: 81–87. doi:10.1016/j.prrv.2020.07.003. PMC 7387280. PMID 32792288.
  72. ^ a b Fialkowski A, Gernez Y, Arya P, et al. (July 2020). "Insight into the pediatric and adult dichotomy of COVID-19: age-related differences in the immune response to SARS-CoV-2 infection". Pediatric Pulmonology. 55 (10): 2556–2564. doi:10.1002/ppul.24981. PMID 32710693.
  73. ^ Radia T, Williams N, Agrawal P, et al. (August 2020). "Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation". Paediatric Respiratory Reviews. 38: 51–57. doi:10.1016/j.prrv.2020.08.001. PMC 7417920. PMID 32891582.
  74. ^ Sardu C, Gambardella J, Morelli MB, et al. (2020). "Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence". Journal of Clinical Medicine. 9 (5): 1417. doi:10.3390/jcm9051417. PMC 7290769. PMID 32403217.
  75. ^ Irfan O, Tang K, Arii M, Bhutta ZA (June 2020). "Epidemiology, spectrum, and impact of COVID-19 on children, adolescents, and pregnant women" (PDF). ipa-world.org (Joint IPA-UNICEF COVID-19 information brief). International Pediatric Association, UNICEF. Retrieved 25 November 2020.
  76. ^ a b c d Loke YH, Berul CI, Harahsheh AS (July 2020). "Multisystem inflammatory syndrome in children: is there a linkage to Kawasaki Disease?". Trends in Cardiovascular Medicine. 30 (7): 389–396. doi:10.1016/j.tcm.2020.07.004. PMC 7370900. PMID 32702413.
  77. ^ a b c d Kam KQ, Ong JS, Lee JH (July 2020). "Kawasaki disease in the COVID-19 era: a distinct clinical phenotype?". The Lancet. Child & Adolescent Health. 4 (9): 642–643. doi:10.1016/S2352-4642(20)30207-8. PMC 7833489. PMID 32622377.
  78. ^ a b Dufort EM, Koumans EH, Chow EJ, et al. (June 2020). "Multisystem inflammatory syndrome in children in New York State". The New England Journal of Medicine. 383 (4): 347–358. doi:10.1056/NEJMoa2021756. PMC 7346766. PMID 32598830.
  79. ^ a b Belot A, Antona D, Renolleau S, et al. (2020). "SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020". Eurosurveillance. 25 (22). doi:10.2807/1560-7917.ES.2020.25.22.2001010. PMC 7336112. PMID 32524957.
  80. ^ a b Verdoni L, Mazza A, Gervasoni A, et al. (2020). "An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study". The Lancet. 395 (10239): 1771–1778. doi:10.1016/S0140-6736(20)31103-X. PMC 7220177. PMID 32410760.
  81. ^ Davies P, Evans C, Kanthimathinathan HK, et al. (July 2020). "Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study". The Lancet. Child & Adolescent Health. 4 (9): 669–677. doi:10.1016/S2352-4642(20)30215-7. PMC 7347350. PMID 32653054.
  82. ^ a b Ouldali N, Pouletty M, Mariani P, et al. (July 2020). "Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis". The Lancet. Child & Adolescent Health. 4 (9): 662–668. doi:10.1016/S2352-4642(20)30175-9. PMC 7332278. PMID 32622376.
  83. ^ a b c "Multisystem Inflammatory Syndrome in Children (MIS-C)". cdc.com. Centers for Disease Control and Prevention. 15 July 2020. Archived from the original on 17 July 2020. As of 7/15/2020, CDC has received reports of 342 cases and 6 deaths in 37 jurisdictions... the majority of MIS-C patients have been Hispanic/Latino or Non-Hispanic Black....Additional studies into MIS-C are needed to learn why certain racial or ethnic groups may be affected in greater numbers...
  84. ^ Hogan, Alexander H.; Herbst, Katherine W.; Defelice, Carlie; Schulman, Noah; Adams, Aaron M.; Carroll, Christopher L.; Salazar, Juan C. (13 March 2024). "Going Viral: Assessing the Impact of Social Media on Enrollment in a Coronavirus Disease 2019 (COVID-19) Cohort Study". Cureus. 13 (3). doi:10.7759/cureus.56096. PMC 11009901.
  85. ^ a b c Wiwanitkit V (June 2020). "COVID-19 and Kawasaki syndrome". Cardiology in the Young. 30 (9): 1372. doi:10.1017/S1047951120001894. PMC 7322145. PMID 32618551.
  86. ^ Kim YJ, Park H, Choi YY, et al. (June 2020). "Defining association between COVID-19 and the multisystem inflammatory syndrome in children through the pandemic". Journal of Korean Medical Science. 35 (22): e204. doi:10.3346/jkms.2020.35.e204. PMC 7279946. PMID 32508068.
  87. ^ a b c Kim H, Shim JY, Ko JH, et al. (November 2020). "Multisystem inflammatory syndrome in children related to COVID-19: the first case in Korea". Journal of Korean Medical Science. 35 (43): e391. doi:10.3346/jkms.2020.35.e391. PMC 7653165. PMID 33169560.
  88. ^ Yung CF, Nadua KD, Oh BK, Thoon KC (July 2020). "Epidemiological trends in Kawasaki disease during COVID-19 in Singapore". The Journal of Pediatrics. 226: 314–315. doi:10.1016/j.jpeds.2020.07.063. PMC 7380241. PMID 32717229.
  89. ^ Xu S, Chen M, Weng J (May 2020). "COVID-19 and Kawasaki disease in children". Pharmacological Research. 159: 104951. doi:10.1016/j.phrs.2020.104951. PMC 7247462. PMID 32464327.
  90. ^ a b Семенова, Мария (17 June 2020). "В Москве умер первый ребенок из-за новой болезни, вызванной COVID-19" (in Russian). RIA Novosti. Retrieved 18 June 2020.
  91. ^ a b Dhanalakshmi K, Venkataraman A, Balasubramanian S, et al. (August 2020). "Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome - temporally associated with SARS-CoV-2 (PIMS-TS) in Indian children". Indian Pediatrics. 57 (11): 1010–1014. doi:10.1007/s13312-020-2025-1. PMC 7678572. PMID 32769230.
  92. ^ a b Rauf A, Vijayan A, John ST, Krishnan R, Latheef A (May 2020). "Multisystem inflammatory syndrome with features of atypical Kawasaki disease during COVID-19 pandemic". Indian Journal of Pediatrics. 87 (9): 745–747. doi:10.1007/s12098-020-03357-1. PMC 8823324. PMID 32462354.
  93. ^ a b Sadiq M, Aziz OA, Kazmi U (August 2020). "Multisystem inflammatory syndrome associated with COVID-19 in children in Pakistan". The Lancet Child & Adolescent Health. 4 (10): e36 – e37. doi:10.1016/S2352-4642(20)30256-X. PMC 7417160. PMID 32791052.
  94. ^ a b Ali M (20 August 2020). "Kazakh ministry refutes claims about Kawasaki syndrome outbreak in children amid COVID-19". www.urdupoint.com. UrduPoint. Archived from the original on 21 August 2020.
  95. ^ a b "S. Korea confirms 2 MIS-C cases". Yonhap News Agency. 5 October 2020. Archived from the original on 31 October 2020.
  96. ^ a b Akca UK, Kesici S, Ozsurekci Y, et al. (September 2020). "Kawasaki-like disease in children with COVID-19". Rheumatology International. 40 (12): 2105–2115. doi:10.1007/s00296-020-04701-6. PMC 7492688. PMID 32936318.
  97. ^ a b Bahrami A, Vafapour M, Moazzami B, Rezaei N (July 2020). "Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: first case from Iran". Journal of Paediatrics and Child Health. 57 (6): 922–925. doi:10.1111/jpc.15048. PMC 7361532. PMID 32640066.
  98. ^ a b Mamishi S, Heydari H, Aziz-Ahari A, et al. (August 2020). "Novel coronavirus disease 2019 (COVID-19) outbreak in children in Iran: atypical CT manifestations and mortality risk of severe COVID-19 infection". Journal of Microbiology, Immunology, and Infection. 54 (5): 839–844. doi:10.1016/j.jmii.2020.07.019. PMC 7406416. PMID 32814650.
  99. ^ Al Ameer HH, AlKadhem SM, Busaleh F, et al. (September 2020). "Multisystem inflammatory syndrome in children temporally related to COVID-19: a case report from Saudi Arabia". Cureus. 12 (9): e10589. doi:10.7759/cureus.10589. PMC 7580961. PMID 33110725.
  100. ^ a b "New inflammatory syndrome". Sheba Medical Center. 25 May 2020. Archived from the original on 11 July 2020.
  101. ^ a b Regev T, Antebi M, Eytan D, et al. (June 2020). "Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-CoV-2 infection". The Pediatric Infectious Disease Journal. 39 (8): e206 – e207. doi:10.1097/INF.0000000000002804. PMID 32639461.
  102. ^ a b Saada H. "Algeria registers first case of Kawasaki disease". DZ Breaking. Archived from the original on 11 July 2020.
  103. ^ a b Webb K, Abraham DR, Faleye A, et al. (August 2020). "Multisystem inflammatory syndrome in children in South Africa". The Lancet Child & Adolescent Health. 4 (10): S2352464220302728. doi:10.1016/S2352-4642(20)30272-8. PMC 7442431. PMID 32835654. S2CID 221217603.
  104. ^ COVID-19 National Incident Room Surveillance Team (September 2020). "COVID-19, Australia: Epidemiology Report 25 (Fortnightly reporting period ending 13 September 2020)". Communicable Diseases Intelligence. 44. doi:10.33321/cdi.2020.44.77. PMID 32981492.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  105. ^ Rowley AH (July 2020). "Diagnosing SARS-CoV-2 related multisystem inflammatory syndrome in children (MIS-C): focus on the gastrointestinal tract and the myocardium". Clinical Infectious Diseases. 72 (9): e402 – e403. doi:10.1093/cid/ciaa1080. PMC 7454389. PMID 32717055.
  106. ^ a b Rowley AH (June 2020). "Multisystem inflammatory syndrome in children and Kawasaki disease: two different illnesses with overlapping clinical features". The Journal of Pediatrics. 224: 129–132. doi:10.1016/j.jpeds.2020.06.057. PMC 7308002. PMID 32585239.
  107. ^ Levin M (June 2020). "Childhood multisystem inflammatory syndrome - a new challenge in the pandemic". The New England Journal of Medicine. 383 (4): 393–395. doi:10.1056/NEJMe2023158. PMC 7346677. PMID 32598829.
  108. ^ a b c Yeung RS, Ferguson PJ (July 2020). "Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?". The Journal of Clinical Investigation. 130 (11): 5681–5684. doi:10.1172/JCI141718. PMC 7598074. PMID 32730226.
  109. ^ a b Rowley AH, Shulman ST, Arditi M (September 2020). "Immune pathogenesis of COVID-19-related multisystem inflammatory syndrome in children (MIS-C)". The Journal of Clinical Investigation. 130 (11): 5619–5621. doi:10.1172/JCI143840. PMC 7598032. PMID 32870815.
  110. ^ a b c Most ZM, Hendren N, Drazner MH, Perl TM (August 2020). "The striking similarities of multisystem inflammatory syndrome in children and a myocarditis-like syndrome in adults: overlapping manifestations of COVID-19". Circulation. 143 (1): 4–6. doi:10.1161/CIRCULATIONAHA.120.050166. PMID 32787714.
  111. ^ a b Jones VG, Mills M, Suarez D, et al. (2020). "COVID-19 and Kawasaki disease: novel virus and novel case" (PDF). Hospital Pediatrics. 10 (6): 537–540. doi:10.1542/hpeds.2020-0123. PMID 32265235. S2CID 215406465.
  112. ^ Mahase E (2020). "COVID-19: concerns grow over inflammatory syndrome emerging in children". BMJ. 369: m1710. doi:10.1136/bmj.m1710. PMID 32345602. The alert, which relayed information from NHS England, said, 'It has been reported that over the past three weeks there has been an apparent rise in the number of children of all ages presenting with a multisystem inflammatory state requiring intensive care across London and other regions of the UK.'
  113. ^ Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P (7 May 2020). "Hyperinflammatory shock in children during COVID-19 pandemic". The Lancet. 395 (10237): 1607–1608. doi:10.1016/S0140-6736(20)31094-1. PMC 7204765. PMID 32386565. During a period of 10 days in mid-April, 2020, we noted an unprecedented cluster of eight children with hyperinflammatory shock, showing features similar to atypical Kawasaki disease, Kawasaki disease shock syndrome, or toxic shock syndrome (typical number is one or two children per week). This case cluster formed the basis of a national alert.
  114. ^ "Rising cases of kids with Kawasaki disease possibly linked to coronavirus". Kyodo News. 30 April 2020. Archived from the original on 13 May 2020. Retrieved 22 May 2020.
  115. ^ Daskalakis, DC (4 May 2020). "2020 Health alert #13: pediatric multi-system inflammatory syndrome potentially associated with COVID-19" (PDF). NYC Health. Archived (PDF) from the original on 6 May 2020.
  116. ^ "Governor Cuomo announces State is helping to develop the national criteria for identifying and responding to COVID-related illness in children". Governor Andrew M. Cuomo. 9 May 2020. Archived from the original on 10 May 2020.
  117. ^ "Coronavirus: Children affected by rare Kawasaki-like disease". BBC News. 14 May 2020. Retrieved 24 May 2020.
  118. ^ d'Adhémar, Margaux (15 May 2020). "Coronavirus : 135 enfants français atteints d'une forme proche de la maladie de Kawasaki, un mort". Le Figaro.fr (in French). Retrieved 16 May 2020.
  119. ^ Deloughry, Rachel (26 May 2020). "20 children in the Netherlands contract illness thought to be linked to COVID-19". www.iamexpat.nl. Retrieved 27 May 2020.
  120. ^ "COVID-19 Fragen und Antworten Teil 11". Paediatrica (in German). 12 May 2020. Retrieved 16 May 2020.
  121. ^ Irmer, Juliette (15 May 2020). ""Kawasaki" durch Covid-19?: Auch deutsche Kinder mit schweren Entzündungsreaktionen". Faz.net (in German). Retrieved 16 May 2020.
  122. ^ "With over 200 possible cases, doctors warn reports of rare, coronavirus-linked child inflammatory illness likely to rise". ABC News. 15 May 2020. Retrieved 16 May 2020.
  123. ^ McNamara, Audrey (13 May 2020). "15 states now investigating child illness possibly linked to coronavirus, Cuomo says". www.cbsnews.com. Retrieved 14 May 2020.
  124. ^ Marsh, Julia; Musumeci, Natalie (18 May 2020). "145 NYC kids have rare Kawasaki-like disease linked to coronavirus". New York Post. Retrieved 19 May 2020.
  125. ^ a b Feldstein LR, Rose EB, Horwitz SM, et al. (June 2020). "Multisystem inflammatory syndrome in U.S. children and adolescents". The New England Journal of Medicine. 383 (4): 334–346. doi:10.1056/NEJMoa2021680. PMC 7346765. PMID 32598831.
  126. ^ "Infographic: Early Cases of MIS-C: Multi-System Inflammatory Syndrome in U.S. Children". cdc.gov. Centers for Disease Control and Prevention. 9 July 2020. Archived from the original on 10 July 2020.
  127. ^ Whittaker E, Bamford A, Kenny J, et al. (June 2020). "Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2". JAMA. 324 (3): 259–269. doi:10.1001/jama.2020.10369. PMC 7281356. PMID 32511692.
  128. ^ Ramcharan T, Nolan O, Lai CY, et al. (June 2020). "Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital". Pediatric Cardiology. 41 (7): 1391–1401. doi:10.1007/s00246-020-02391-2. PMC 7289638. PMID 32529358.
  129. ^ Cabrero-Hernández M, García-Salido A, Leoz-Gordillo I, et al. (May 2020). "Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain". The Pediatric Infectious Disease Journal. 39 (8): e195 – e198. doi:10.1097/INF.0000000000002777. PMID 32467457. S2CID 218984945.
  130. ^ Moraleda C, Serna-Pascual M, et al. (July 2020). "Multi-inflammatory syndrome in children related to SARS-CoV-2 in Spain". Clinical Infectious Diseases. 72 (9): e397 – e401. doi:10.1093/cid/ciaa1042. PMC 7454331. PMID 32710613.
  131. ^ Pino R, Izurieta AC, Ríos-Barnés M, et al. (August 2020). "Correspondence on: 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al". Annals of the Rheumatic Diseases. 81 (9): annrheumdis-2020-218538. doi:10.1136/annrheumdis-2020-218538. PMID 32759264. S2CID 220974885.
  132. ^ Belhadjer Z, Méot M, Bajolle F, et al. (2020). "Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic". Circulation. 142 (5): 429–436. doi:10.1161/CIRCULATIONAHA.120.048360. PMID 32418446. S2CID 218679879.
  133. ^ Grimaud M, Starck J, Levy M, et al. (June 2020). "Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children". Annals of Intensive Care. 10 (1): 69. doi:10.1186/s13613-020-00690-8. PMC 7266128. PMID 32488505.
  134. ^ Toubiana J, Poirault C, Corsia A, et al. (June 2020). "Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study". BMJ. 369: m2094. doi:10.1136/bmj.m2094. PMC 7500538. PMID 32493739.
  135. ^ Chiotos K, Bassiri H, Behrens EM, et al. (May 2020). "Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series". Journal of the Pediatric Infectious Diseases Society. 9 (3): 393–398. doi:10.1093/jpids/piaa069. PMC 7313950. PMID 32463092.
  136. ^ Kaushik S, Aydin SI, Derespina KR, et al. (June 2020). "Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection: a multi-institutional study from New York City". The Journal of Pediatrics. 224: 24–29. doi:10.1016/j.jpeds.2020.06.045. PMC 7293760. PMID 32553861.
  137. ^ Cheung EW, Zachariah P, Gorelik M, et al. (June 2020). "Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City". JAMA. 324 (3): 294–296. doi:10.1001/jama.2020.10374. PMC 7281352. PMID 32511676.
  138. ^ "U.S. counts 342 child inflammatory syndrome cases". TribLIVE.com. Associated Press. 16 July 2020. Archived from the original on 17 July 2020.
  139. ^ Jenco M (16 July 2020). "CDC: 71% of MIS-C patients Hispanic or Black". AAP News. American Academy of Pediatrics. Archived from the original on 17 July 2020.
  140. ^ "Australian Health Protection Principal Committee (AHPPC) coronavirus (COVID-19) statements on 14 May 2020". Australian Government Department of Health. 15 May 2020. Archived from the original on 24 May 2020.
  141. ^ Barraclough B (18 May 2020). "Chances of Kiwi kids contracting mysterious syndrome linked to Covid-19 'very low', but authorities on the lookout". TVNZ. Archived from the original on 2 June 2020.
  142. ^ Yáñez JA, Alvarez-Risco A, Delgado-Zegarra J (June 2020). "COVID-19 in Peru: from supervised walks for children to the first case of Kawasaki-like syndrome". BMJ. 369: m2418. doi:10.1136/bmj.m2418. hdl:20.500.12724/11105. PMID 32571770. S2CID 219970740.
  143. ^ "COVID-19: aparece primer caso de Kawasaki en Perú". Panamericana Televisión (in Spanish). 2 June 2020. Archived from the original on 10 June 2020.
  144. ^ Pereira MF, Litvinov N, Farhat SC, et al. (2020). "Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome". Clinics (Sao Paulo). 75: e2209. doi:10.6061/clinics/2020/e2209. PMC 7426591. PMID 32844958.
  145. ^ a b de Farias EC, Pedro Piva J, de Mello ML, et al. (August 2020). "Multisystem inflammatory syndrome associated with coronavirus disease in children: a multi-centered study in Belém, Pará, Brazil". The Pediatric Infectious Disease Journal. 39 (11): e374 – e376. doi:10.1097/INF.0000000000002865. PMID 32826724.
  146. ^ Torres JP, Izquierdo G, Acuña M, et al. (August 2020). "Multisystem inflammatory syndrome in children (MIS-C): report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic". International Journal of Infectious Diseases. 100: 75–81. doi:10.1016/j.ijid.2020.08.062. PMC 7452906. PMID 32861823.
  147. ^ Shah SK, Munoz AC (July 2020). "Multisystem inflammatory syndrome in children in COVID-19 pandemic". Indian Journal of Pediatrics. 87 (9): 671–673. doi:10.1007/s12098-020-03440-7. PMC 7332842. PMID 32621172.
  148. ^ Jain S, Sen S, Lakshmivenkateshiah S, et al. (August 2020). "Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India". Indian Pediatrics. 57 (11): 1015–1019. doi:10.1007/s12098-020-03497-4. ISSN 0019-5456. PMC 7678602. PMID 32788432. S2CID 221674522.
  149. ^ Saxena A (18 July 2020). "Delhi hospitals see Kawasaki-like symptoms in children with Covid". The Indian Express. Archived from the original on 18 July 2020.
  150. ^ "Kawasaki syndrome or MIS-C: Children recovering from COVID-19 also face the brunt of the disease". Firstpost. 20 July 2020. Archived from the original on 20 July 2020. Retrieved 20 July 2020.
  151. ^ Khan KS, Ullah I (July 2020). "SARS-CoV-2 causes Kawasaki like disease in children; cases reported in Pakistan". Journal of Medical Virology. 93 (1): 20–21. doi:10.1002/jmv.26340. PMC 7405107. PMID 32706410.
  152. ^ Umer D, Ahmed T (8 July 2020). "Post-coronavirus Kawasaki-like inflammatory syndrome reported in eight children in Lahore". Samaa TV. Archived from the original on 9 July 2020.
  153. ^ "Egypt free from Kawasaki disease: Cabinet". EgyptToday. 10 July 2020. Archived from the original on 11 July 2020.
  154. ^ "45 casos probables de menores con síndrome inflamatorio multisistémico". Teleamazonas (in Spanish). 19 July 2020. Archived from the original on 20 July 2020.
  155. ^ "Costa Rica registra récord de casos diarios y niños con peligroso síndrome". www.diariolibre.com (in European Spanish). Diario Libre. 29 August 2020. Archived from the original on 31 August 2020.
  156. ^ Scott S, McElroy N (4 September 2020). "A children's inflammatory illness associated with COVID-19 has emerged in Australia. Here's what we know". ABC news. Retrieved 4 September 2020.
  157. ^ a b Wood, S (22 July 2020). "COVID-19's Kawasaki-like MIS-C diagnosis is cropping up in adults". TCTMD.com. Archived from the original on 23 July 2020.
  158. ^ Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J (June 2020). "Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection". Journal of Medical Virology. 93 (1): 139–140. doi:10.1002/jmv.26229. PMC 7361787. PMID 32592496.
  159. ^ "Youngest Israeli victim: 26-year-old man dies from rare complication of COVID-19". Times of Israel. 14 June 2020. Archived from the original on 6 July 2020.
  160. ^ Sokolovsky S, Soni P, Hoffman T, Kahn P, Scheers-Masters J (June 2020). "COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult". The American Journal of Emergency Medicine. 39: 253.e1–253.e2. doi:10.1016/j.ajem.2020.06.053. PMC 7315983. PMID 32631771.
  161. ^ Jones I, Bell L, Manson J, Last A (July 2020). "An adult presentation consistent with PIMS-TS". The Lancet Rheumatology. 2 (9): e520 – e521. doi:10.1016/S2665-9913(20)30234-4. PMC 7351404. PMID 32838310. S2CID 220460929.
  162. ^ Shaigany S, Gnirke M, Guttmann A, et al. (July 2020). "An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19". The Lancet. 396 (10246): e8 – e10. doi:10.1016/S0140-6736(20)31526-9. PMC 7351414. PMID 32659211.
  163. ^ Fox SE, Lameira FS, Rinker EB, Vander Heide RS (July 2020). "Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19". Annals of Internal Medicine. 173 (12): 1025–1027. doi:10.7326/L20-0882. PMC 7506743. PMID 32726150.
  164. ^ Chérif MY, de Filette JM, André S, et al. (August 2020). "Coronavirus disease 2019-related Kawasaki-like disease in an adult: a case report". JAAD Case Reports. 6 (8): 780–782. doi:10.1016/j.jdcr.2020.06.023. PMC 7311326. PMID 32754629.
  165. ^ Lidder AK, Pandit SA, Lazzaro DR (December 2020). "An adult with COVID-19 kawasaki-like syndrome and ocular manifestations". American Journal of Ophthalmology Case Reports. 20: 100875. doi:10.1016/j.ajoc.2020.100875. PMC 7437437. PMID 32839740.
  166. ^ Chowdhary A, Joy E, Plein S, Abdel-Rahman SE (September 2020). "Multisystem inflammatory syndrome in an adult with SARS-CoV-2 infection". European Heart Journal: Cardiovascular Imaging. 22 (5): e17. doi:10.1093/ehjci/jeaa232. PMC 7499519. PMID 32887992.
  167. ^ American Academy of Neurology (13 April 2021). "73rd AAN ANNUAL MEETING ABSTRACT (PDF)" (PDF). Retrieved 20 April 2021.
  168. ^ Belluck, Pam (13 April 2021). "Some Children With Covid-Related Syndrome Develop Neurological Symptoms". The New York Times. ISSN 0362-4331. Retrieved 20 April 2021.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Multisystem_inflammatory_syndrome_in_children&oldid=1231513453"